ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy. The purpose of this study was to evaluate the role of ERCC1 expression as a predictive marker of sur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2008-07, Vol.99 (1), p.167-172
Hauptverfasser:	Jun, H J, Ahn, M J, Kim, H S, Yi, S Y, Han, J, Lee, S K, Ahn, Y C, Jeong, H-S, Son, Y-I, Baek, J-H, Park, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - therapy Chemotherapy Cisplatin - therapeutic use Combined Modality Therapy DNA repair DNA-Binding Proteins - biosynthesis Drug Resistance Endonucleases - biosynthesis Epidemiology Female Head & neck cancer Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - therapy Humans Immunohistochemistry Magnetic resonance imaging Male Medical research Medical sciences Medicine Middle Aged Molecular Diagnostics Molecular Medicine Oncology Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Predictive Value of Tests Radiation therapy Radiotherapy Survival Analysis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!